ATE174219T1 - Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha - Google Patents

Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha

Info

Publication number
ATE174219T1
ATE174219T1 AT94100016T AT94100016T ATE174219T1 AT E174219 T1 ATE174219 T1 AT E174219T1 AT 94100016 T AT94100016 T AT 94100016T AT 94100016 T AT94100016 T AT 94100016T AT E174219 T1 ATE174219 T1 AT E174219T1
Authority
AT
Austria
Prior art keywords
necrosis factor
factor alpha
leflunomide
tumor necrosis
inhibit tumor
Prior art date
Application number
AT94100016T
Other languages
German (de)
English (en)
Inventor
Klaus Ulrich Dr Weithmann
Robert Ryder Dr Bartlett
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of ATE174219T1 publication Critical patent/ATE174219T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94100016T 1993-01-08 1994-01-03 Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha ATE174219T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4300280 1993-01-08

Publications (1)

Publication Number Publication Date
ATE174219T1 true ATE174219T1 (de) 1998-12-15

Family

ID=6477855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94100016T ATE174219T1 (de) 1993-01-08 1994-01-03 Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha

Country Status (8)

Country Link
US (1) US5547970A (https=)
EP (1) EP0607776B1 (https=)
JP (1) JPH06234637A (https=)
AT (1) ATE174219T1 (https=)
DE (1) DE59407414D1 (https=)
DK (1) DK0607776T3 (https=)
ES (1) ES2124801T3 (https=)
GR (1) GR3029490T3 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1997042820A1 (en) 1996-05-16 1997-11-20 Duke University Tristetraprolin
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
ATE196764T1 (de) * 1997-08-08 2000-10-15 Aventis Pharma Gmbh Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
DE69937904T2 (de) * 1998-03-11 2009-01-02 James W. Oak Park Williams Antivirale verwendungen von leflunomid produkten
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
EP1414517A4 (en) * 2001-06-26 2008-02-06 Photomed Technologies Inc Multiple wavelength illuminator
AU2003299971A1 (en) * 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
EP1763346A4 (en) * 2004-05-21 2009-03-04 Uab Research Foundation COMPOSITIONS AND METHODS RELATED TO PYRIMIDINE SYNTHESIS
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
WO2017037022A1 (en) * 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
WO1992002822A1 (en) * 1990-08-06 1992-02-20 Cetus Corporation Methods for the identification of cytokine convertase inhibitors

Also Published As

Publication number Publication date
DK0607776T3 (da) 1999-08-16
EP0607776A3 (https=) 1994-08-31
US5547970A (en) 1996-08-20
DE59407414D1 (de) 1999-01-21
ES2124801T3 (es) 1999-02-16
EP0607776B1 (de) 1998-12-09
GR3029490T3 (en) 1999-05-28
JPH06234637A (ja) 1994-08-23
EP0607776A2 (de) 1994-07-27

Similar Documents

Publication Publication Date Title
DE59407414D1 (de) Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
DE59407413D1 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
DK130387D0 (da) Transglutaminase inhibitorer
ATE259640T1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE69954T1 (de) Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
DE69733834D1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
ATE222489T1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69329558D1 (de) Verfahren zur Behandlung von Multiplesklerose
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
ATE174220T1 (de) Verwendung von leflunomid zur hemmung von interleukin 8
EA200001124A1 (ru) Способ генной терапии
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE59407412D1 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
DE59302465D1 (de) Verwendung von bärlauch zur therapie oder prophylaxe von durchblutungsstörungen
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
ATE105186T1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.